IKT - Inhibikase Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

1.104M

Cash

9.749M

Avg Qtr Burn

-3.995M

Short % of Float

0.89%

Insider Ownership

12.43%

Institutional Own.

14.38%

Qtr Updated

03/31/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
IkT-001Pro Details Hematologic malignancies, Gastric cancer, Cancer	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Risvodetinib Details Parkinson's disease, Neurodegenerative disease	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.